Recombinant monoclonal antibody to Integrin Integrin alpha 5 beta 1. Volociximab (also known as M200) is a chimeric monoclonal antibody jointly for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.
It is thought to reduce metastases. Early results show potential in renal cell cancers.
- The details of the immunogen for this antibody are not available.
- Chimeric (mouse/human)
- Tested positive against native human antigen.
- Species Reactivity
- Suitable for use in IP, IF, FuncS, FC, Neut, ELISA, ICC and most other immunological methods.
- CAS NO.
- Generic Name
- 145.5 kDa
- Related Disease
- Alternative Names
- Volociximab; 558480-40-3; M200; ITGA5; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); FNRA; integrin alpha-5; CD49e
- Entrez Gene ID
- UniProt ID
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us